You are here: Industry Insights > LUYE PHARMA

News List

Luye Pharma’s Shares Drop on Acquisition of Two Biological Antibodies firstwordpharma
December 25, 2018
Luye Pharma announced that it acquired the biological monoclonal antibodies, LY01011 and LY09004, from Shandong Boan Biological Technology for nearly $73 million, reported Investing.com.
Luye Pharma receives China approval for CNS drug biospectrumasia
July 24, 2018
Luye Pharma acquired the rights for Seroquel (Quetiapine Fumarate) and Seroquel XR from AstraZeneca in 51 countries and regions, including China, with the acquisition finalized in June 2018.
LUYE pharma Joins US Firm to Develop Immuno-oncology Treatments biospectrumasia
May 30, 2018
The most advanced next generation dual-targeted CAR-T cell therapy drug derived from the Collaboration is in the IND enabling preclinical study stage
Luye Pharma acquires AstraZeneca's signature products biospectrumasia
May 29, 2018
A Move Aimed at Enriching the Existing CNS Portfolio and Enhancing Strategic Synergy across International Markets
AstraZeneca sells rights for Seroquel to China's Luye Pharma biospectrumasia
May 10, 2018
In FY 2017, Seroquel generated annual sales of $85mn
Luye Pharma: A Healthy Thirty Percent Annual Growth Rate, with Competitive Product Pipelines across Different Therapeutic Areas prnasia
March 30, 2018
One of China's leading pharmaceutical companies, Luye Pharma (02186. HK), released its annual results on March 26, 2018

Previous page 1 2 Next page